After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
Josh Moon has been appointed Chief Operating Officer (COO) at Creative Testing Solutions (CTS), effe...
Celebrate National Blood Donor Month throughout January by inviting eligible individuals to donate b...
Reminder - Five CTS Forms will be updated on Monday September 2, 2019. Some of the forms are posted ...
The CTS forms listed below have been revised with an implementation date of September 2, 2019. ...
CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly...
As a service to our partners, CTS provides a copy of all licenses and accreditations on our website....